

VRL/SEC/EXCHANGE

10.02.2016

<p>National Stock Exchange of India Ltd. 5th Floor, Exchange Plaza Bandra (E), Mumbai- 400 051</p>	<p>Dept. of Corporate Services The Stock Exchange, Mumbai 25th Floor, Phiroze Jeejeebhoy Towers Dalal Street Mumbai</p>
--	---

Sub.: Outcome of Board Meeting

Dear Sir,

This is to inform you that, the Board of Directors of the Company at its meeting held today considered and approved the Unaudited Financial Results (Provisional) for the quarter ended 31.12.2015.

Thanking you.

Yours faithfully,
for **VENUS REMEDIES LIMITED.**


(Company Secretary)
Neha Kodan
(Company Secretary)



VENUS REMEDIES LIMITED

Corporate Office :
51-52, Industrial Area, Phase- I,
Panchkula (Hry.) 134113, India
Regd. Office :

SCO 857, Cabin No. 10, 2nd Floor, NAC,
Manimajra, Chandigarh (U.T.) 160101, India
Website : www.venusremedies.com
www.venusmedicineresearchcentre.com
email : info@venusremedies.com
CIN No. : L24232CH1989PLC009705



Unit-I :
51-52, Industrial Area, Phase-I, Panchkula (Hry.) 134113, India
Tel. : +91-172-3933094, 3933090, 2565577, Fax : +91-172-2565566
Unit-II :
Hill Top Industrial Estate, Jharmajri EPIP, Phase-I, (Extn.),
Bhatoli Kalan, Baddi (H.P.) 173205, India
Tel. : +91-1795-302100, 302101, 302107, Fax : +91-1795-271272
Unit-V :
VENUS PHARMA GmbH
AM Bahnhof 1-3, D-59368, Werne, Germany

VRL/SEC/EXCHANGE

10.02.2016

<p>National Stock Exchange of India Ltd. 5th Floor , Exchange Plaza Bandra (E), Mumbai- 400 051</p>	<p>Dept. of Corporate Services The Stock Exchange, Mumbai 25th Floor, Phiroze Jeejeebhoy Towers Dalal Street Mumbai</p>
---	---

Sub: Submission of Unaudited Financial results as on 31.12.2015

Dear Sir/Madam,


Please find enclosed herewith copy of Unaudited Financial Results (provisional) along with limited review report for the quarter ended on 31.12.2015 which were taken on record by the Board of Directors at its meeting held on 10.02.2016.

Kindly acknowledge the receipt.

Thanking you.

Yours faithfully,
for **VENUS REMEDIES LIMITED.**


Neha Kodan (Company Secretary)
(Company Secretary)



VENUS REMEDIES LIMITED

Corporate Office :
51-52, Industrial Area, Phase-I,
Panchkula (Hry.) 134113, India
Regd. Office :
SCO 857, Cabin No. 10, 2nd Floor, NAC,
Manimajra, Chandigarh (U.T.) 160101, India
Website : www.venusremedies.com
www.venusmedicineresearchcentre.com
email : info@venusremedies.com
CIN No. : L24232CH1989PLC009705



Unit-I :
51-52, Industrial Area, Phase-I, Panchkula (Hry.) 134113, India
Tel. : +91-172-3933094, 3933090, 2565577, Fax : +91-172-2565566
Unit-II :
Hill Top Industrial Estate, Jharmajri EPIP, Phase-I, (Extn.),
Bhatoli Kalan, Baddi (H.P.) 173205, India
Tel. : +91-1795-302100, 302101, 302107, Fax : +91-1795-271272
Unit-V :
VENUS PHARMA GmbH
AM Bahnhof 1-3, D-59368, Werne, Germany

UNAUDITED FINANCIAL RESULTS (PROVISIONAL)
FOR THE QUARTER ENDED 31st DECEMBER, 2015

(Rs. In Millions)

S. No.	PARTICULARS	Quarter Ended on			Nine Months Ended on		Year Ended on
		31/12/2015 Unaudited	30/09/2015 Unaudited	31/12/2014 Unaudited	31/12/2015 Unaudited	31/12/2014 Unaudited	
Part - I							
1	Net Sales/ Income from operations						
	(a) Net Sales (Net of Excise Duty)	966.76	1008.66	1051.65	2960.61	3513.53	4497.45
	(b) Other Operating Income	17.41	50.78	3.99	72.12	16.41	21.3
	Total Income from Operation (Net)	984.17	1,059.44	1,055.64	3,032.73	3,529.94	4,518.75
2	Expenses						
	(a) Cost of material consumed	604.02	654.64	595.00	1848.67	2008.17	2,643.89
	(b) Change in inventories of finished goods, work in progress & stock in trade	(10.73)	(7.58)	37.48	(12.76)	87.91	65.28
	(c) Employee benefits expense	52.88	61.51	68.05	176.11	200.46	272.55
	(d) Depreciation & amortisation expense	101.72	101.06	83.00	302.38	276.59	447.41
	(e) Other expenses	157.88	147.58	167.88	445.26	482.57	667.70
	Total expense	905.77	957.21	951.41	2,759.66	3,055.70	4,096.83
3	Profit/ (Loss) from operations before other income , finance costs and exceptional items (1-2)	78.40	102.23	104.23	273.07	474.24	421.92
	EBIDTA (3+2(d))	180.12	203.3	187.23	575.45	750.83	869.33
4	Other income	0.76	1.19	1.16	2.99	3.28	5.46
5	Profit / (Loss) before finance costs and exceptional items (3+4)	79.16	103.42	105.39	276.06	477.52	427.38
6	Finance Costs	81.70	87.37	83.97	260.52	250.57	407.03
7	Profit / (Loss) after finance costs but before exceptional items (5-6)	(2.54)	16.05	21.42	15.54	226.95	20.35
8	Exceptional items	0.00	0.00	0.00	0.00	0.00	00.00
9	Profit / (Loss) from ordinary activities before tax (7+8)	(2.54)	16.05	21.42	15.54	226.95	20.35
10	Tax expense	0.00	0.00	0.00	0.00	0.00	25.13
11	Profit / (Loss) from ordinary activities after tax (9-10)	(2.54)	16.05	21.42	15.54	226.95	45.48
12	Extraordinary items (net of tax expense)	00.00	00.00	00.00	0.00	0.00	0.00
13	Net profit/ (Loss) for the period (11-12)	(2.54)	16.05	21.42	15.54	226.95	45.48
14	Paid up Equity Share Capital (Face value of Rs. 10/- per share)	114.42	114.42	114.42	114.42	114.42	114.42
15	Reserves excluding revaluation reserves	N. A.	N. A.	N. A.	N. A.	N. A.	4,547.93
16	E.P.S - Basic not annualised for the qtr	(0.22)	1.40	1.87	1.02	14.88	3.97
	- Annualised	(0.89)	5.61	7.49	1.36	19.84	3.97
Part - II							
1	Public Shareholding						
	- Number of Shares	7711988	7711988	7711988	7711988	7711988	7711988
	- Percentage of Shareholding	67.40	67.40	67.40	67.40	67.40	67.40
2	Promoters and promoter group shareholding						
a)	Pledged as collateral security to bank						
	- Number of Shares	3630000	3630000	1430000	3630000	1430000	3730000
	- Percentage of shares (as a % of the total share holding of promoter and promoter group	97.32	97.32	38.34	97.32	38.34	100.00
	- Percentage of shares (as a % of the total share capital	31.73	31.73	12.50	31.73	12.50	32.60
b)	Non-Encumbered						
	- Number of Shares	100000	100000	2300000	100000	2300000	0.00
	- Percentage of shares (as a % of the total share holding of promoter and promoter group	02.68	02.68	61.66	02.68	61.66	00.00
	- Percentage of shares (as a % of the total share capital	00.87	00.87	20.10	00.87	20.10	00.00


For VENUS REMEDIES LIMITED

CHAIRMAN & MANAGING DIRECTOR

Notes:

1. The above financial Results were reviewed by the Audit Committee and taken on record at the Board Meeting on February 10, 2016.
2. The Company caters to only one segment i.e. "Pharmaceutical Formulations"

Date: 10.02.2016

For and on behalf of Board of Directors
For **VENUS REMEDIES LIMITED**
For VENUS REMEDIES LIMITED

CHAIRMAN & MANAGING DIRECTOR
Pawan Chaudhary
(Chairman & Managing Director)
DIN: 00435503



VENUS REMEDIES LIMITED

Corporate Office :
51-52, Industrial Area, Phase-I,
Panchkula (Hry.) 134113, India
Regd. Office :
SCO 857, Cabin No. 10, 2nd Floor, NAC,
Manimajra, Chandigarh (U.T.) 160101, India
Website : www.venusremedies.com
www.venusmedicineresearchcentre.com
email : info@venusremedies.com
CIN No. : L24232CH1989PLC009705



Unit-I :
51-52, Industrial Area, Phase-I, Panchkula (Hry.) 134113, India
Tel. : +91-172-3933094, 3933090, 2565577, Fax : +91-172-2565566
Unit-II :
Hill Top Industrial Estate, Jharmajri EPIP Phase-I, (Extn.),
Bhatoli Kalan, Baddi (H.P.) 173205, India
Tel. : +91-1795-302100, 302101, 302107, Fax : +91-1795-271272
Unit-V :
VENUS PHARMA GmbH
AM Bahnhof 1-3, D-59368, Werne, Germany



Stress Reliever with Liver Detoxifier & Antioxidant Property



A German Technology



J.K. JAIN & ASSOCIATES

CHARTERED ACCOUNTANTS

S.C.O. 1132-33, Sector 22-B, CHANDIGARH - 160 022

0172-270 4536-37 Fax : 0172-270 4537

E-mail : jkcaps@rediffmail.com

REVIEW REPORT

The Board of Directors,
Venus Remedies Limited
51-52, Industrial Area, Phase-I
Panchkula

We have reviewed the accompanying statement of un-audited Financial Results of **Venus Remedies Limited** for the Quarter / Nine Months ended 31.12.2015. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors/Committee of Board Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, 'Engagements to Review financial statements' issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of un-audited Quarterly/ Nine Monthly financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing obligations and Disclosure Requirements) Regulation 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

for J. K. Jain & Associates,
(Chartered Accountants)

Avdhesh Gupta

(CA Avdesh Gupta)

Partner

M.No. 537795

FRN No. 004025N



Date : 10.02.2016

Place : Chandigarh